Conquering the dark side: colloidal iron oxide nanoparticles.
Nanomedicine approaches to atherosclerotic disease will have significant impact on the practice and outcomes of cardiovascular medicine. Iron oxide nanoparticles have been extensively used for nontargeted and targeted imaging applications based upon highly sensitive T2* imaging properties, which typically result in negative contrast effects that can only be imaged 24 or more hours after systemic administration due to persistent blood pool interference. Although recent advances involving MR pulse sequences have converted these dark contrast voxels into bright ones, the marked delays in imaging from persistent magnetic background interference and prominent dipole blooming effects of the magnetic susceptibility remain barriers to overcome. We report a T1-weighted (T1w) theranostic colloidal iron oxide nanoparticle platform, CION, which is achieved by entrapping oleate-coated magnetite particles within a cross-linked phospholipid nanoemulsion. Contrary to expectations, this formulation decreased T2 effects thus allowing positive T1w contrast detection down to low nanomolar concentrations. CION, a vascular constrained nanoplatform administered in vivo permitted T1w molecular imaging 1 h after treatment without blood pool interference, although some T2 shortening effects on blood, induced by the superparamagnetic particles, persisted. Moreover, CION was shown to encapsulate antiangiogenic drugs, like fumagillin, and retained them under prolonged dissolution, suggesting significant theranostic functionality. Overall, CION is a platform technology, developed with generally recognized as safe components, that overcomes the temporal and spatial imaging challenges associated with current iron oxide nanoparticle T2 imaging agents and which has theranostic potential in vascular diseases for detecting unstable ruptured plaque or treating atherosclerotic angiogenesis.
Senpan
Angana
A
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63108, USA.
Caruthers
Shelton D
SD
Rhee
Ilsu
I
Mauro
Nicholas A
NA
Pan
Dipanjan
D
Hu
Grace
G
Scott
Michael J
MJ
Fuhrhop
Ralph W
RW
Gaffney
Patrick J
PJ
Wickline
Samuel A
SA
Lanza
Gregory M
GM
D050197:Atherosclerosis / Q000473:pathology*; D003102:Colloids / Q000737:chemistry; D003287:Contrast Media / Q000737:chemistry; D003460:Crystallization / Q000379:methods; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D066298:In Vitro Techniques; D046911:Macromolecular Substances / Q000737:chemistry; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008422:Materials Testing; D008968:Molecular Conformation; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D013499:Surface Properties
D003102:Colloids; D003287:Contrast Media; D005290:Ferric Compounds; D046911:Macromolecular Substances; C000499:ferric oxide